ArticleChinese medicine2026
Qing-Chang-Hua-Shi granule ameliorates experimental colitis by modulating Lactobacillus gasseri-mediated ferroptosis metabolic pathway.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundUlcerative colitis (UC) is a chronic inflammatory disorder marked by epithelial barrier disruption and persistent intestinal inflammation. Despite extensive research, its complex etiology continues to pose therapeutic challenges. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has recently been implicated in UC pathogenesis. Additionally, the gut microbiota and its metabolites play a pivotal role in maintaining intestinal homeostasis and barrier integrity. PURPOSE: This study aimed to investigate the therapeutic potential of a phytotherapeutic agent QCHS to alleviate UC by modulating ferroptosis and the microbiota-metabolome axis, with a particular focus on the role of Lactobacillus gasseri (L. gasseri).
methodsA DSS-induced UC mouse model was used to evaluate QCHS efficacy. Gut microbial composition and metabolomic alterations were analyzed via 16S rDNA sequencing and UHPLC-MS/MS. L. gasseri was cultured in vitro to assess the impact of QCHS on its growth. RSL3-induced cell death was modeled in NCM-460 cells and ferroptosis-related changes were examined using transmission electron microscopy, immunohistochemistry, quantitative PCR, and Western blotting.
resultsQCHS significantly mitigated DSS-induced ferroptosis in colonic tissues, with L. gasseri identified as a key mediator. Notably, L. gasseri was found to act as a novel ferroptosis inhibitor. In vitro studies confirmed that L. gasseri suppressed RSL3-induced ferroptosis in NCM-460 cells via activation of the GSH/GPX4 pathway.
conclusionThis study provides compelling evidence for the regulatory role of QCHS on the microbiota-metabolome axis and ferroptosis in UC. It also uncovers a novel function of L. gasseri as a ferroptosis inhibitor, offering promising insights into microbiota-targeted and ferroptosis-modulating therapeutic strategies for UC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.